

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED
大健康國際集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2211)

**POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING
HELD ON 30 JANUARY 2024**

References are made to the circular (the “**Circular**”) and the notice of extraordinary general meeting (the “**Notice**”) of Universal Health International Group Holding Limited (the “**Company**”) both dated 12 January 2024 despatched to its shareholders (the “**Shareholder(s)**”). At the extraordinary general meeting (the “**EGM**”) of the Company held on 30 January 2024, the proposed resolution (the “**Proposed Resolution**”) as set out in the Notice was taken by poll.

As at the date of the EGM, the total number of issued shares of the Company was 667,549,632 shares, which was the total number of shares entitling the holders to attend and vote for or against the Proposed Resolution. There were no shares entitling the holders to attend and abstain from voting in favour of the Proposed Resolution as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and no Shareholder was required under the Listing Rules to abstain from voting at the EGM.

No parties have stated their intention in the Circular to vote against or abstain from voting on the Proposed Resolution.

Mazars CPA Limited was appointed as the scrutineer at the EGM for the purpose of vote-taking. The poll results in respect of the Proposed Resolution at the EGM was as follows:

| ORDINARY RESOLUTION | Number of votes cast (Approximate percentage of total number of votes cast) | |
|--|--|-----------------|
| | For | Against |
| <p>(i) to ratify, confirm and approve the equity transfer agreement dated 3 November 2023 entered into between Heilongjiang JintianAixin Pharmaceutical Distribution Limited* (黑龍江省金天愛心醫藥經銷有限公司) as vendor and Sifengdeshan Pharmaceutical Limited* (西豐德善藥業有限公司) as purchaser relating to the sale and purchase of 100% equity interest in Shenyang Weishi Pharmaceutical Limited* (瀋陽衛世醫藥有限公司) (the “Agreement”); and</p> <p>(ii) to authorise any one director of the Company to sign, execute, perfect, perform and deliver all such other agreements, instruments, deeds and documents and do all such acts or things and take all such steps as they may in their absolute discretion consider to be necessary, desirable, appropriate or expedient to implement or give effect to or otherwise in connection with or incidental to the Agreement and all the transactions contemplated thereunder and to agree to such variations, amendments or waivers as are, in the opinion of such director of the Company, in the interests of the Company and its shareholders.</p> | 114,686,565 shares (100%) | 0 share (0%) |

Please refer to the Circular and the Notice for the full version of the Proposed Resolution. As more than 50% of the votes were cast in favour of the Proposed Resolution at the EGM, the Proposed Resolution was duly passed as ordinary resolution of the Company.

Mr. Chu Chuanfu and Mr. Zhao Zehu, both are executive directors of the Company, attended the EGM in person, while the other directors of the Company were unable to attend due to other business engagements.

By order of the Board
Universal Health International Group Holding Limited
Chu Chuanfu
Chairman and Executive Director

Hong Kong, 30 January 2024

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Chu Chuanfu, Mr. Jin Dongkun and Mr. Zhao Zehua and three independent non-executive Directors, namely Mr. Cheng Sheung Hing, Ms. Chiang Su Hui Susie and Mr. Zou Haiyan.

** For ease of reference, the names of the PRC established companies or entities have generally been included in this announcement in both Chinese and English languages and in the event of inconsistency, the Chinese language shall prevail.*